Inside Amylyx's headquarters in Cambridge, MA (courtesy Amylyx/Kathy Wong for Endpoints News)

Fresh off ALS drug with­draw­al, Amy­lyx touts in­ter­im rare dis­ease da­ta for the same ther­a­py

A week af­ter vol­un­tar­i­ly pulling its ALS drug off the mar­ket fol­low­ing a failed Phase 3 tri­al, Amy­lyx Phar­ma­ceu­ti­cals …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.